BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 11029510)

  • 1. New aromatase inhibitors in the treatment of advanced breast cancer.
    Crucitta E; Lorusso V; Attolico M; Sambiasi D; Mazzei A; De Lena M
    Int J Oncol; 2000 Nov; 17(5):1037-41. PubMed ID: 11029510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of aromatase inhibitors in breast carcinoma.
    Santen RJ; Harvey HA
    Endocr Relat Cancer; 1999 Mar; 6(1):75-92. PubMed ID: 10732791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of aromatase inhibitors in the treatment of metastatic breast cancer.
    Mouridsen H; Gershanovich M
    Semin Oncol; 2003 Aug; 30(4 Suppl 14):33-45. PubMed ID: 14513435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A roundtable discussion of aromatase inhibitors as therapy for breast cancer.
    Allred DC; Baum M; Buzdar AU; Carlson RW; Dowsett M; Elledge RM; Gradishar WJ; Grana G; Howell A; Mamounas EP
    Breast J; 2003; 9(3):213-22. PubMed ID: 12752630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on letrozole or anastrozole. A phase II trial conducted by the Hellenic Group of Oncology (HELGO).
    Gennatas C; Michalaki V; Carvounis E; Psychogios J; Poulakaki N; Katsiamis G; Voros D; Kouloulias V; Mouratidou D; Tsavaris N
    Tumori; 2006; 92(1):13-7. PubMed ID: 16683378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    Rose C
    Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of anti-aromatase agents in postmenopausal advanced breast cancer.
    Murray R
    Cancer Chemother Pharmacol; 2001 Oct; 48(4):259-65. PubMed ID: 11710624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.
    Roseman BJ; Buzdar AU; Singletary SE
    J Surg Oncol; 1997 Nov; 66(3):215-20. PubMed ID: 9369969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exemestane as first-line therapy in postmenopausal women with recurrent or metastatic breast cancer.
    Glück S
    Am J Clin Oncol; 2010 Jun; 33(3):314-9. PubMed ID: 19730353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS
    Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
    Hamilton A; Volm M
    Oncology (Williston Park); 2001 Aug; 15(8):965-72; discussion 972, 977-9. PubMed ID: 11548977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approval summary: letrozole in the treatment of postmenopausal women with advanced breast cancer.
    Cohen MH; Johnson JR; Li N; Chen G; Pazdur R
    Clin Cancer Res; 2002 Mar; 8(3):665-9. PubMed ID: 11895893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exemestane versus anastrozole as front-line endocrine therapy in postmenopausal patients with hormone receptor-positive, advanced breast cancer: final results from the Spanish Breast Cancer Group 2001-03 phase 2 randomized trial.
    Llombart-Cussac A; Ruiz A; Antón A; Barnadas A; Antolín S; Alés-Martínez JE; Alvarez I; Andrés R; García Saenz JA; Lao J; Carrasco E; Cámara C; Casas I; Martín M
    Cancer; 2012 Jan; 118(1):241-7. PubMed ID: 21717449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
    Gori S; Anastasi P; Marrocolo F
    Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206
    [No Abstract]   [Full Text] [Related]  

  • 17. Should aromatase inhibitors replace tamoxifen?
    Drug Ther Bull; 2003 Aug; 41(8):57-9. PubMed ID: 12966738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase inhibitors in advanced breast cancer.
    Mouridsen HT
    Semin Oncol; 2004 Dec; 31(6 Suppl 12):3-8. PubMed ID: 15719595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New aromatase inhibitors for the treatment of advanced breast cancer in postmenopausal women.
    de Jong PC; Blijham GH
    Neth J Med; 1999 Aug; 55(2):50-8. PubMed ID: 10474272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A summary of second-line randomized studies of aromatase inhibitors.
    Buzdar AU
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):109-14. PubMed ID: 11850214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.